tert-butyl (2-(carbamoyloxy)ethyl)carbamate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: tert-butyl (2-(carbamoyloxy)ethyl)carbamate
• 英文别名: N-boc-2-aminoethyl carbamate；tert-butyl N-(2-carbamoyloxyethyl)carbamate
• 化学式: C₈H₁₆N₂O₄
• 分子量: 204.226
• InChiKey: WUPIBYKZHPEFKI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  14
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  90.6
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  亚磷酸三苯酯 、 tert-butyl (2-(carbamoyloxy)ethyl)carbamate 、 4-(三氟乙酰氨基)苯甲醛 在 copper(II) bis(trifluoromethanesulfonate) 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 以29%的产率得到2-((tert-butoxycarbonyl)amino)ethyl ((diphenoxyphosphoryl)(4-(2,2,2-trifluoroacetamido)phenyl)methyl)carbamate
  参考文献：
  名称：

  α-氨基二苯基膦酸酯是大肠杆菌ClpP蛋白酶的新型抑制剂

  摘要：

  革兰氏阴性细菌对抗生素的耐药性日益成为全球性问题，因此需要具有新颖作用机制的新型抗生素。酪蛋白水解蛋白酶亚基P（ClpP）是一种在细菌中保守的丝氨酸蛋白酶，被认为是一种有趣的药物靶标。ClpP功能与蛋白质代谢和体内稳态，应激反应以及其他过程中的毒力有关。这项研究的重点是确定大肠杆菌ClpP的新抑制剂并了解其作用方式。测试了基于二芳基膦酸酯战斗部的丝氨酸蛋白酶抑制剂的重点文库对ClpP的抑制作用，并对命中化合物进行了化学探索。总共有14种新的强效大肠杆菌抑制剂确定了ClpP。化合物85和92分别由于其效力以及适度但一致的抗菌特性以及有利的细胞毒性特性而成为本研究中最令人感兴趣的化合物。

  DOI：

  10.1021/acs.jmedchem.8b01466

文献信息

• [EN] NOVEL KLK4 INHIBITORS<br/>[FR] NOUVEAUX INHIBITEURS DE KLK4
  申请人：UNIV ANTWERPEN

  公开号：WO2015144933A1

  公开（公告）日：2015-10-01

  The present invention relates to novel compounds and probes which have a common chemical structure necessary to obtain potent inhibitory activity against KLK4 and/or may be used for the detection of KLK4 peptides and their activity. It further relates to the use of these compounds and methods for inhibiting and/or detecting KLK4 activity in vitro and in vivo by making use of said probes or inhibitors. The compounds of the invention differ from prior art compounds at least in the presence of phenyl guanidine (instead of e.g. benzyl guanidine) and/or the presence of a heteroatom in the tail group, their combined presence unexpectedly leading to potent and selective KLK4 inhibitory activity.

  本发明涉及具有共同化学结构的新化合物和探针，这种结构对于获得强大的对KLK4的抑制活性是必要的，或者可用于检测KLK4肽及其活性。它进一步涉及利用这些化合物和方法通过利用所述的探针或抑制剂来抑制和/或检测体外和体内的KLK4活性。本发明的化合物与先前的化合物不同，至少在于存在苯基胍（而不是苄基胍等）和/或尾基中存在杂原子，它们的共同存在意外地导致强大和选择性的KLK4抑制活性。
• Inhibitors of IMPDH enzyme
  申请人：VERTEX PHARMACEUTICALS INCORPORATED

  公开号：EP1964561A1

  公开（公告）日：2008-09-03

  The present invention relates to compounds which inhibit JMPDH. This invention also relates to pharmaceutical compositions comprising these compounds. The compounds and pharmaceutical compositions of this invention are particularly well suited for inhibiting JMPDH enzyme activity and consequently, may be advantageously used as therapeutic agents for IMPDH-mediated processes. This invention also relates to methods for inhibiting the activity of I1VIPDH using the compounds of this invention and related compounds.

  本发明涉及抑制 JMPDH 的化合物。本发明还涉及包含这些化合物的药物组合物。本发明的化合物和药物组合物特别适用于抑制 JMPDH 酶的活性，因此可作为 IMPDH 介导过程的治疗剂。本发明还涉及使用本发明化合物及相关化合物抑制 I1VIPDH 活性的方法。
• KLK4 inhibitors
  申请人：Universiteit Antwerpen

  公开号：US10017527B2

  公开（公告）日：2018-07-10

  The present invention relates to novel compounds and probes which have a common chemical structure necessary to obtain potent inhibitory activity against KLK4 and/or may be used for the detection of KLK4 peptides and their activity. It further relates to the use of these compounds and methods for inhibiting and/or detecting KLK4 activity in vitro and in vivo by making use of said probes or inhibitors. The compounds of the invention differ from prior art compounds at least in the presence of phenyl guanidine (instead of e.g. benzyl guanidine) and/or the presence of a heteroatom in the tail group, their combined presence unexpectedly leading to potent and selective KLK4 inhibitory activity.

  本发明涉及新型化合物和探针，它们具有获得对 KLK4 的强效抑制活性所需的共同化学结构和/或可用于检测 KLK4 肽及其活性。本发明还涉及这些化合物的用途，以及利用所述探针或抑制剂抑制和/或检测体外和体内 KLK4 活性的方法。本发明化合物与现有技术化合物的不同之处至少在于苯基胍（而不是苄基胍）的存在和/或尾部基团中杂原子的存在，它们的联合存在意外地导致了强效和选择性的 KLK4 抑制活性。
• NOVEL KLK4 INHIBITORS
  申请人：Universiteit Antwerpen

  公开号：US20170101427A1

  公开（公告）日：2017-04-13

  The present invention relates to novel compounds and probes which have a common chemical structure necessary to obtain potent inhibitory activity against KLK4 and/or may be used for the detection of KLK4 peptides and their activity. It further relates to the use of these compounds and methods for inhibiting and/or detecting KLK4 activity in vitro and in vivo by making use of said probes or inhibitors. The compounds of the invention differ from prior art compounds at least in the presence of phenyl guanidine (instead of e.g. benzyl guanidine) and/or the presence of a heteroatom in the tail group, their combined presence unexpectedly leading to potent and selective KLK4 inhibitory activity.
• α-Amino Diphenyl Phosphonates as Novel Inhibitors of <i>Escherichia coli</i> ClpP Protease
  作者：Carlos Moreno-Cinos、Elisa Sassetti、Irene G. Salado、Gesa Witt、Siham Benramdane、Laura Reinhardt、Cristina D. Cruz、Jurgen Joossens、Pieter Van der Veken、Heike Brötz-Oesterhelt、Päivi Tammela、Mathias Winterhalter、Philip Gribbon、Björn Windshügel、Koen Augustyns

  DOI：10.1021/acs.jmedchem.8b01466

  日期：2019.1.24

  Increased Gram-negative bacteria resistance to antibiotics is becoming a global problem, and new classes of antibiotics with novel mechanisms of action are required. The caseinolytic protease subunit P (ClpP) is a serine protease conserved among bacteria that is considered as an interesting drug target. ClpP function is involved in protein turnover and homeostasis, stress response, and virulence among

  革兰氏阴性细菌对抗生素的耐药性日益成为全球性问题，因此需要具有新颖作用机制的新型抗生素。酪蛋白水解蛋白酶亚基P（ClpP）是一种在细菌中保守的丝氨酸蛋白酶，被认为是一种有趣的药物靶标。ClpP功能与蛋白质代谢和体内稳态，应激反应以及其他过程中的毒力有关。这项研究的重点是确定大肠杆菌ClpP的新抑制剂并了解其作用方式。测试了基于二芳基膦酸酯战斗部的丝氨酸蛋白酶抑制剂的重点文库对ClpP的抑制作用，并对命中化合物进行了化学探索。总共有14种新的强效大肠杆菌抑制剂确定了ClpP。化合物85和92分别由于其效力以及适度但一致的抗菌特性以及有利的细胞毒性特性而成为本研究中最令人感兴趣的化合物。